Rgenta Therapeutics
Signal active
Organization
Contact Information
Overview
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.
It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics, Oncology
Founded
2018
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Rgenta Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $16.8B in funding across 144 round(s). With a team of 11-50 employees, Rgenta Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Rgenta Therapeutics, raised $8.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
6
Investors
2
Lead Investors
0
Total Funding Amount
$116.9M
Details
4
Rgenta Therapeutics has raised a total of $116.9M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Seed | 20.0M | ||
| 2021 | Seed | 18.0M | ||
| 2022 | Early Stage Venture | 52.0M | ||
| 2023 | Early Stage Venture | 8.0M |
Investors
Rgenta Therapeutics is funded by 35 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Highlight Capital | - | FUNDING ROUND - Highlight Capital | 8.0M |
| Lore Gruenbaum | - | FUNDING ROUND - Lore Gruenbaum | 8.0M |
| Rgenta Therapeutics | - | FUNDING ROUND - Rgenta Therapeutics | 8.0M |
| The Leukemia & Lymphoma Society’s Therapy Acceleration Program | - | FUNDING ROUND - The Leukemia & Lymphoma Society’s Therapy Acceleration Program | 8.0M |
Recent Activity
There is no recent news or activity for this profile.